Glimepiride Tablets, USP, 4 mg, RX, Packaged as a) 100-count bottle, NDC# 68001-179-00; b) 500-co...

FDA Drug Recall #D-0759-2023 — Class II — March 17, 2023

Recall Summary

Recall Number D-0759-2023
Classification Class II — Moderate risk
Date Initiated March 17, 2023
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Amerisource Health Services LLC
Location Columbus, OH
Product Type Drugs
Quantity 129,849 bottles

Product Description

Glimepiride Tablets, USP, 4 mg, RX, Packaged as a) 100-count bottle, NDC# 68001-179-00; b) 500-count bottle, NDC# 68001-179-03, Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213. INDIA. For BluePoint Laboratories

Reason for Recall

CGMP Deviations: recalling drug products following an FDA inspection.

Distribution Pattern

Nationwide USA

Lot / Code Information

Batches a) P2003403, EXP 05/31/2023; P2006593, EXP 11/30/2023; P2101152, EXP 01/31/2024; P2105014, EXP 06/30/2024; R2101440, EXP 09/30/2024; P2200774, EXP 01/31/2025; R2200664, EXP 04/30/2025 b) P2100705, EXP 01/31/2024; P2104672, EXP 06/30/2024; R2101435, EXP 09/30/2024; R2200102, EXP 12/31/2024; R2200577, EXP 04/30/2025; P2205870, EXP 08/31/2025 [500 count] Lot, expiry: P2100121, exp 11/30/2023; P2100705, exp 01/31/2024; P2104672, exp 06/30/2024; R2101435, exp 09/30/2024; R2200102, exp 12/31/2024; R2200577, exp R2200577;P2205870, exp 08/31/2025

Other Recalls from Amerisource Health Services LLC

Recall # Classification Product Date
D-0537-2026 Class III Primidone Tablets, USP, 50 mg, 100 Tablets (10 ... May 1, 2026
D-0536-2026 Class III Primidone Tablets, USP, 250 mg, 100 Tablets (10... May 1, 2026
D-0418-2026 Class II Meclizine Hydrochloride Tablets, USP 12.5 mg, (... Mar 16, 2026
D-0338-2026 Class II Oxycodone Hydrochloride Tablets, USP (CII), 5 m... Jan 14, 2026
D-0101-2026 Class II Prazosin Hydrochloride, Capsules, USP, 1 mg, 10... Oct 16, 2025

Frequently Asked Questions

cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.